Compare DexCom, Inc. (DXCM) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MakeMyTrip Ltd — how do they compare? DexCom, Inc. trades at $90.76 (market cap $33.79B), while MakeMyTrip Ltd trades at $60.56 (market cap $5.78B). The key difference: DexCom, Inc. is far larger — about 5.8× MakeMyTrip Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | MMYT | |
|---|---|---|
Market Cap | $33.79B | $5.78B |
Sector | Health | Technology |
52-Week High | $90.80 | $103.21 |
52-Week Low | $54.84 | $36.30 |
Enterprise Value | $33.24B | $6.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
MakeMyTrip (MMYT) trades at $60.31, down 0.99% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth to $978M in 2025 and consistent earnings beats, though Q2 2026 missed expectations. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target. Recent news highlights travel industry momentum despite temporary air-ticketing softness.
Investment outlook appears favorable with strong fundamentals and bullish analyst consensus, though risks include rising debt levels and geopolitical travel disruptions. The stock's high P/E ratio of 267 requires sustained earnings growth to justify valuation. Recent institutional selling by Boston Common Asset Management warrants monitoring for broader sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
